Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference
December 03 2014 - 7:00AM
Business Wire
Dyax Corp. (NASDAQ: DYAX) announced today that executive
management will participate in the 25th Annual Oppenheimer
Healthcare Conference being held December 10-11, 2014 at the Crowne
Plaza Hotel in New York City. The Company is scheduled to present
on Wednesday, December 10 at 10:20am (ET) and will provide a
corporate update on the KALBITOR® (ecallantide) business, DX-2930
and the Licensing and Funded Research Portfolio (LFRP).
This presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the company’s website at
http://investor.dyax.com/events.cfm. The webcast will also be
available on the Dyax website for a limited period of time
following the conference.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on
the discovery, development and commercialization of novel
biotherapeutics for unmet medical needs. The Company currently
markets KALBITOR® (ecallantide) for the treatment of acute attacks
of hereditary angioedema (HAE) in patients 12 years of age and
older. Dyax is also developing DX-2930 a fully human monoclonal
antibody, for the potential prophylactic treatment of HAE.
Both KALBITOR and DX-2930 were identified using Dyax's
proprietary phage display technology. Dyax has broadly licensed
this technology and has a portfolio of product candidates being
developed by its licensees, which it refers to as the LFRP. The
Company is eligible to receive future milestones and/or royalties
dependent upon the development and commercialization of these
candidates. In 2014, Dyax’s licensee Eli Lilly and Company began
marketing their FDA approved product, CYRAMZA® (ramucirumab), as a
single-agent treatment for patients with advanced gastric cancer
after prior chemotherapy, making this the first royalty-bearing
product from Dyax’s LFRP.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking statements.
Statements that are not historical facts are based on Dyax’s
current expectations, beliefs, assumptions, estimates, forecasts
and projections about the industry and markets in which Dyax
operates. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements because of
risks, uncertainties and assumptions involved in any future
projections. There are many factors that could cause actual results
to differ from these forward-looking statements, including: risks
and uncertainties relating to the clinical development of DX-2930;
Dyax’s dependence on the expertise, effort, priorities and
contractual obligations of third parties in the development of
DX-2930 and in the marketing, sales and distribution of KALBITOR;
competition from new and existing treatments for HAE; the
uncertainty of patent and intellectual property protection relating
to DX-2930, KALBITOR and the LFRP; Dyax's dependence on licensees
and collaborators for development, clinical trials, manufacturing,
sales and distribution of product candidates in the LFRP;
uncertainties as to whether one or more product candidates in the
LFRP will achieve development and regulatory milestones and be
commercialized and generate royalties; uncertainties regarding
Lilly's ability to successfully market CYRAMZA for the treatment of
advanced gastric cancer; and other risk factors described or
referred to in Item 1A, “Risk Factors” in Dyax’s most recent Annual
Report on Form 10-K and other periodic reports filed with the
Securities and Exchange Commission. Dyax cautions investors not to
place undue reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this
release, and Dyax undertakes no obligations to update or revise
these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered marks
of Dyax Corp.
CYRAMZA® is a registered trademark of Eli Lilly and Company.
DyaxJennifer Robinson, 617-250-5741Director, Investor Relations
and Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Sep 2023 to Sep 2024